Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Would you consider lenvatinib plus everolimus as first line treatment for a patient with tuberous sclerosis and metastatic renal cell carcinoma?
Related Questions
Do you need renal biopsy before SBRT for RCC suspicious cancer?
Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
Is there any evidence for combining surgery and XRT +/- ADT for treatment of localized high risk prostate cancer?
What would be your recommended regimen for an AYA patient with relapsed mediastinal pure seminoma, with relapse 20 months after completion of BEP?
In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?
For patients with high-volume hormone-sensitive prostate cancer, would you consider shortening the docetaxel course to 4 cycles to facilitate better tolerance?
What therapy would you use for a patient with metastatic TFE3 rearranged RCC who progressed on initial pembrolizumab/lenvatinib?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
